72 related articles for article (PubMed ID: 15878437)
21. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
22. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine.
Krishnan-Natesan S; Chandrasekar PH; Manavathu EK; Revankar SG
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):443-6. PubMed ID: 18842377
[TBL] [Abstract][Full Text] [Related]
25. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
27. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
Chamilos G; Kontoyiannis DP
Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of current drug therapies for invasive aspergillosis.
Traunmüller F; Popovic M; Konz KH; Smolle-Jüttner FM; Joukhadar C
Pharmacology; 2011; 88(3-4):213-24. PubMed ID: 21986253
[TBL] [Abstract][Full Text] [Related]
29. Aspergillus species intrinsically resistant to antifungal agents.
Van Der Linden JW; Warris A; Verweij PE
Med Mycol; 2011 Apr; 49 Suppl 1():S82-9. PubMed ID: 20662634
[TBL] [Abstract][Full Text] [Related]
30. Azole resistance in Aspergillus: global status in Europe and Asia.
Arikan-Akdagli S
Ann N Y Acad Sci; 2012 Dec; 1272():9-14. PubMed ID: 23231709
[TBL] [Abstract][Full Text] [Related]
31. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species.
Fakhim H; Badali H; Dannaoui E; Nasirian M; Jahangiri F; Raei M; Vaseghi N; Ahmadikia K; Vaezi A
J Mycol Med; 2022 Nov; 32(4):101310. PubMed ID: 35907396
[TBL] [Abstract][Full Text] [Related]
32. In vitro susceptibility testing in Aspergillus species: an update.
Lass-Flörl C
Future Microbiol; 2010 May; 5(5):789-99. PubMed ID: 20441550
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
Pastor FJ; Guarro J
Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
